ARTICLE | Top Story
MGI, JNJ Dacogen deal
July 7, 2006 1:20 AM UTC
MOGN granted Johnson & Johnson (JNJ) exclusive rights to develop and commercialize Dacogen decitabine outside of North America. The hypomethylating agent, which was approved to treat myelodysplastic s...